The Latest Breaking News from Awakn

(Part four of a four-part series - Read part three)

(Part three of a four-part series)

This article by Freddie Earlam was originally published on Microdose and appears here with permission. If the industry-defining research already conducted at UK centers such as Imperial College, King’s college or even Exeter University’s recent Ketamine Research isn’t enough to convince you, then two more crucial factors surely will. Firstly, a new ‘accelerated pathway’ has…

Awakn Life Sciences (OTC: AWKNF) is in the news after a respected analyst has upgraded the stock.  Awakn is a publicly traded company which trades on the over-the-counter market with the symbol of 

This article was originally published on Psychedelic Spotlight and appears here with permission. While psychedelic studies now number in the thousands since Western research began in the 1950s, we unpack five of the most important in recent years as psychedelics are on the cusp of becoming mainstream medicines. When it…

Awakn Life Sciences (OTC: AWKNF) is not only going after alcoholism but also binge eating disorder, compulsive sexual behavior and even Internet gaming disorder.

Psychedelics are being touted as a cure for depression, addiction and PTSD — but will this new industry live up to the hype? As the Australian government announces that it will legalise MDMA and magic mushrooms for medical use, Alexandra Jones visits London’s first clinic to find out whether the…

New Awakn Study Shows Ketamine Has Potential To Treat Alcoholism